GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Edesa Biotech Inc (NAS:EDSA) » Definitions » Cyclically Adjusted PB Ratio

EDSA (Edesa Biotech) Cyclically Adjusted PB Ratio : 0.02 (As of May. 29, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Edesa Biotech Cyclically Adjusted PB Ratio?

As of today (2025-05-29), Edesa Biotech's current share price is $1.98. Edesa Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $116.38. Edesa Biotech's Cyclically Adjusted PB Ratio for today is 0.02.

The historical rank and industry rank for Edesa Biotech's Cyclically Adjusted PB Ratio or its related term are showing as below:

EDSA' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.1   Max: 0.34
Current: 0.02

During the past years, Edesa Biotech's highest Cyclically Adjusted PB Ratio was 0.34. The lowest was 0.01. And the median was 0.10.

EDSA's Cyclically Adjusted PB Ratio is ranked better than
97.46% of 670 companies
in the Biotechnology industry
Industry Median: 1.485 vs EDSA: 0.02

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Edesa Biotech's adjusted book value per share data for the three months ended in Mar. 2025 was $0.905. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $116.38 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Edesa Biotech Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Edesa Biotech's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edesa Biotech Cyclically Adjusted PB Ratio Chart

Edesa Biotech Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.28 0.31 0.04 0.02 0.03

Edesa Biotech Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.03 0.01 0.02

Competitive Comparison of Edesa Biotech's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Edesa Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edesa Biotech's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Edesa Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Edesa Biotech's Cyclically Adjusted PB Ratio falls into.


;
;

Edesa Biotech Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Edesa Biotech's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.98/116.38
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edesa Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Edesa Biotech's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.905/129.1809*129.1809
=0.905

Current CPI (Mar. 2025) = 129.1809.

Edesa Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201506 349.370 100.500 449.072
201509 296.481 100.421 381.390
201512 332.103 99.947 429.240
201603 303.897 101.054 388.484
201606 264.172 102.002 334.563
201609 362.176 101.765 459.749
201612 319.559 101.449 406.915
201703 287.941 102.634 362.420
201706 238.806 103.029 299.423
201709 205.528 103.345 256.910
201712 167.194 103.345 208.993
201803 131.667 105.004 161.983
201806 97.535 105.557 119.364
201809 88.874 105.636 108.683
201812 78.016 105.399 95.619
201903 65.118 106.979 78.632
201906 5.796 107.690 6.953
201909 4.903 107.611 5.886
201912 3.950 107.769 4.735
202003 5.475 107.927 6.553
202006 4.220 108.401 5.029
202009 4.826 108.164 5.764
202012 5.246 108.559 6.243
202103 10.187 110.298 11.931
202106 8.344 111.720 9.648
202109 6.876 112.905 7.867
202112 5.463 113.774 6.203
202203 7.707 117.646 8.463
202206 5.359 120.806 5.731
202209 3.946 120.648 4.225
202212 3.715 120.964 3.967
202303 3.140 122.702 3.306
202306 2.633 124.203 2.739
202309 2.292 125.230 2.364
202312 1.847 125.072 1.908
202403 1.345 126.258 1.376
202406 0.883 127.522 0.894
202409 0.610 127.285 0.619
202412 0.370 127.364 0.375
202503 0.905 129.181 0.905

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Edesa Biotech  (NAS:EDSA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Edesa Biotech Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Edesa Biotech's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Edesa Biotech Business Description

Traded in Other Exchanges
N/A
Address
100 Spy Court, Markham, ON, CAN, L3R 5H6
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
Executives
Pardeep Nijhawan director, 10 percent owner, officer: Chief Executive Officer C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Stephen Lemieux officer: Chief Financial Officer 100 SPY COURT, C/O EDESA BIOTECH, INC., MARKHAM A6 L3R 5H6
Joan Chypyha director 100 SPY COURT, MARKHAM A6 L3R 5H6
Patrick Marshall director 100 SPY COURT, MARKHAM A6 L3R 5H6
Van Der Velden Peter director, 10 percent owner C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Michael J Brooks officer: President C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Jennifer M Chao director 7 PURITAN WOODS ROAD, RYE NY 10580
Frank R. Oakes director, officer: President, CEO, & Director C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041
Sean Arthur Macdonald director C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Lorin K Johnson director 3600 W BAYSHORE ROAD SUITE 205, PALO ALTO CA 94303
Pardeep Nijhawan Medicine Professional Corp 10 percent owner C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Paul William Pay director C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Carlo Sistilli director C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Lumira Capital Investment Management Inc. 10 percent owner 141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5
Daniel E. Morse director C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041